On the evening of July 11, Lepu MedicalDisclosure of a suggestive announcement regarding the registration approval of sodium hyaluronate solution for injection by NMPA.

The company learned today that the sodium hyaluronate solution for injection independently developed by its subsidiary Sichuan Xingtai Pule Medical Technology Co., Ltd. has been approved for registration by the National Medical Products Administration (NMPA), with the registration certificate number of National Medical Device Registration No. 20253131324. The product is used in medical institutions for injection into the superficial dermis of the face to temporarily improve dry skin and dull complexion in adults.

The announcement pointed out that the sodium hyaluronate solution for injection is a water light injection product. By accurately injecting nutrients into the superficial or middle layers of the dermis, it effectively solves the problem of skin care products being difficult to absorb through the skin. The successful approval of the sodium hyaluronate solution for injection further enriches the company's product matrix in the field of dermatology, and will play a synergistic role with existing products to meet the increasingly diversified market needs, which will help the company expand its business in the field of consumer medical care and is expected to have a positive impact on the company's development.

Source：https://finance.eastmoney.com/a/202507113454845565.html